All functions |
|
|---|---|
Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. |
|
Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis. |
|
An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. |
|
DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers. |
|
DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers. |
|
Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. |
|
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. |
|
Integrative approach for prioritizing cancer genes in sporadic colon cancer. |
|
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. |
|
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. |
|
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. |
|
MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer. |
|
Expression Project for Oncology (expO) |
|
Clinical significance of osteoprotegerin expression in human colorectal cancer. |
|
Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. |
|
Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. |
|
Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. |
|
A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. |
|
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. |
|
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. |
|
Expression Profiles in Stage II Colon Cancer According to APC Gene Status. |
|
Genome-wide profiling characterizes CRCs with genetic instability and specific routes to HLA class I loss and immunoescape |
|
Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. |
|
Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. |
|
Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. |
|
Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. |
|
Deciphering cellular states of innate tumor drug responses. |
|
Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. |
|
Gene expression signature for recurrence in stage III colorectal cancers. |
|
AMC tubular and serrated adenomas |
|
Comprehensive molecular characterization of human colon and rectal cancer. |
|
Comprehensive molecular characterization of human colon and rectal cancer. |
|
Comprehensive molecular characterization of human colon and rectal cancer. |
|
Comprehensive molecular characterization of human colon and rectal cancer. |
|
Clinically Annotated Data for the CRC Cancer Transcriptome |
|